Ocumetics Technology Corp. announced positive three-month postoperative results from Group 1 patients in its first-in-human clinical study of the Ocumetics Accommodating Intraocular Lens. The results validate the company's core technology and represent a key clinical de-risking milestone as Ocumetics advances toward subsequent study phases. The Group 1 data met or exceeded all predefined internal benchmarks for safety, lens delivery, and foundational distance visual performance, successfully achieving the primary objectives required to progress the clinical program. These results can be best summarized as meeting expectations for safety profile, exceeding expectations for visual acuity outcomes, and meeting expectations for lens delivery system performance.
Group 1 patients entered the study with severe visual impairment, with some presenting uncorrected preoperative acuities as poor as 20/250, levels consistent with legal blindness. Post-implantation outcomes underscore both the clinical effectiveness and real-world impact of the Ocumetics Lens. Dr. Rafael Vázquez MD, principal investigator of the Ocumetics first-in-human trial, stated that all patient outcomes have met safety expectations, and patients have experienced truly life-changing events. From being classified legally blind, patients can now read, enjoy everyday life activities, and drive, with remarkable impact on their independence and sense of freedom.
Dean Burns, President and CEO of Ocumetics, expressed confidence in the technology, stating that following a detailed review of the data with Dr. Raphael Vasquez, the primary surgeon, he remains 100% confident in the accommodating intraocular lens technology. Based on this success, the company has initiated planning for Group 2 surgeries. The company continues to apply its rapid "win-learn" R&D approach, incorporating surgeon feedback in real time to further optimize performance. Based on insights from Group 1, Ocumetics has already implemented refinements to the lens delivery mechanism and initiated multiple lens optimization initiatives aimed at enhancing outcomes in Group 2.
Manufacturing and testing of optimized lens designs are currently underway, with Group 2 surgeries expected to be scheduled following completion of final lens testing and validation. The company announced that Dean Burns will host an exclusive webinar covering the three-month study results and important updates on the FIH study, which can be accessed at https://www.ocumetics.com/webinar. The original release can be viewed on https://www.newmediawire.com.
